Adoption of the First Live-cell Imaging System and the First-ever HCS Workshop
in China
SHANGHAI, China and PITTSBURGH, April 4 /PRNewswire/ -- The National
Center for Drug Screening (NCDS) located in Shanghai, China and Cellomics,
Inc. of Pittsburgh, Pennsylvania, U.S.A. today announced an addition to their
strategic collaboration aimed at expanding the application of High Content
Screening (HCS) technologies in China. Affiliated with the Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, the Center is a key national
technology innovation base in drug discovery and development.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGO )
Cellomics, Inc., a privately held company, is recognized as the creator of
and market leader in HCS, providing a unique cell-based platform to its global
clients in pharmaceutical, biotechnology and academic institutions.
The expansion of this collaboration is facilitated by two key events.
First, the NCDS has completed their HCS portfolio of research and discovery
tools through the acquisition of the KineticScan(R) HCS Reader, Cellomics'
premier instrument for performing live-cell, kinetic HCS assays. The second
part of this expansion includes the organization and sponsorship of a
nationwide HCS Workshop to be held at the NCDS in Shanghai, between April 4
and 6, 2005. This event will bring together 60 researchers selected from more
than 20 major cities, provinces and autonomous regions, who are looking to
bring HCS capabilities into their drug discovery and systems biology research
programs.
"The adoption of Cellomics' live-cell imaging system, the KineticScan HCS
Reader is vital to expanding our research programs in cell-based high content
screening," stated Dr. Ming-Wei Wang, Director of the NCDS. "By adding the
capabilities of the KineticScan to those we already have with Cellomics'
ArrayScan(R) HCS Reader, we are able to quickly execute our strategic plan of
utilizing HCS technologies in our drug discovery and development efforts,"
continued Dr. Wang.
"We are very excited to work with the NCDS to organize the first-ever HCS
workshop in China. Cellomics has been performing HCS Workshops and User Group
Meetings in the U.S. for many years, and we are happy to be able to share our
expertise in this area with drug discovery and research scientists in China,"
stated Dr. Judy Masucci, Director of Marketing at Cellomics. "We are pleased
to be able to send three of our top HCS experts to support this event."
"Our collaboration with Dr. Wang and the NCDS is critically important for
Cellomics," commented Daniel J. Calvo, President and CEO of Cellomics.
"Through this joint effort with China's leading drug discovery facility, we
can expand our global leadership position in HCS into China and the
surrounding region. We look forward to continuing to assist this world-class
laboratory in incorporating our technologies into their research programs, as
well as supporting the expansion of HCS across China," continued Calvo.
About NCDS
The National Center for Drug Screening was jointly set up by the Ministry
of Science and Technology, the Chinese Academy of Sciences and the Shanghai
Municipality Government. It offers a wide-range of drug screening services and
technical consultations to universities, research institutions and commercial
entities across China. Using its advanced technology platforms and high
quality services, and through external collaborations with biopharmaceutical
research and development institutions, the NCDS is playing an indispensable
role in the adequate utilization of compound resources nationwide and
promotion of innovative drug development. Focusing on major diseases that
affect the Chinese population (such as cancer, central nervous system
diseases, metabolic disorders and infectious diseases, etc.), the NCDS is
actively developing internationally advanced drug screening assays, performing
large-scale compound library screening and conducting downstream studies. The
establishment of the NCDS is an important milestone in modernizing China's
drug research and innovation system. For more information, please
visit http://www.screen.org.cn .
About Cellomics
Cellomics, Inc. is automating drug discovery through a unique, cell-based
assay platform that addresses the needs of Drug Discovery and Systems Biology
groups by offering complete systems for High Content Screening. The platform
includes HCS instrumentation (both fixed end-point and kinetic systems),
informatics, cellular image analysis software (BioApplications), fluorescent
reagents, kits, cell lines, and multiparametric assays. When applied to early
drug discovery, this platform is proving to reduce the 'idea-to-discovery'
cycle time in drug discovery, while increasing the probability of the
therapeutic success of leads as well as enhancing throughput in systems
biology and basic research. Cellomics' proprietary platforms, including the
ArrayScan and KineticScan HCS Readers, along with BioApplications software and
High Content Informatics (HCi(TM)) suite, are in use at multiple sites within
all of the top fifteen pharmaceutical companies, as well as leading
pharmaceutical and biotechnology companies and academic centers globally. For
more information about Cellomics, visit our website at http://www.cellomics.com .
For further information, contact:
Judy P. Masucci, Ph.D. Xin Xie, Ph.D.
Director of Marketing Head, Department of Assay Development II
Cellomics, Inc. The National Center for Drug Screening
100 Technology Drive 189 Guo Shou Jing Road
Pittsburgh, PA 15219 Shanghai 201203, P.R. China
412-770-2200 x 2353 21-50801313 x 186
412-770-2450 (fax) 21-50800721 (fax)
pr@cellomics.com xxie@mail.shcnc.ac.cn
http://www.cellomics.com http://www.screen.org.cn
SOURCE Cellomics, Inc.
 back to top
Related links:
http://www.cellomics.com
http://www.screen.org.cn
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Judy P. Masucci, Ph.D., Director of Marketing
of Cellomics, Inc., +1-412-770-2200 x 2353, or fax,
+1-412-770-2450, or pr@cellomics.com ; or Xin Xie, Ph.D., Head,
Department of Assay Development II of The National Center for
Drug Screening, +21-50801313 x 186, or fax, +21-50800721, or
xxie@mail.shcnc.ac.cn
|
